Elucidation of interaction between bone marrow micro-metastases in breast cancer patients

阐明乳腺癌患者骨髓微转移之间的相互作用

• 批准号: 22501056
• 负责人: TAKAHASHI Syunji
• 金额: $ 2.75万
• 依托单位: Japanese Foundation For Cancer Research
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22501056/
• 关键词: 乳癌; 骨転移; 骨髄微小転移; 骨微小環境; ビスホスホネート

To elucidate the interaction of disseminated tumor cells in bone marrow (DTC) and bone microenvironment and the effects of bisphosphonates in early breast cancer, we treated breast cancer patients with neoadjuvant chemotherapy with zoledronic acid (ZA), and examined pathological response and changes of DTC, circulating tumor cells (CTC) and circulating endothelial cells (CEC). We treated 30 patients and had Grade 2 to 3 response in 9 patients. CTC was positive in three patients and all became negative after chemotherapy. CEC increased with chemotherapy. Chemotherapy with ZA may increase CEC, and CEC may become a biomarker of neoadjuvant chemotherapy. DTC was positive in only three patients and tumor cells were few, so it was difficult to investigate interaction between tumor cells and cells in bone micro-environment. It should be necessary to investigate interaction between tumor cells and cells in bone micro-environment in the samples of bone metastases

为探讨骨髓播散性肿瘤细胞（DTC）与骨微环境的相互作用及双膦酸盐在早期乳腺癌中的作用，我们采用唑来膦酸（ZA）新辅助化疗治疗乳腺癌患者，观察DTC、循环肿瘤细胞（CTC）和循环内皮细胞（CEC）的病理反应和变化。我们治疗了30例患者，9例患者出现2 - 3级反应。CTC阳性3例，化疗后均转阴。CEC随着化疗而增加。ZA化疗可增加CEC，CEC可能成为新辅助化疗的生物标志物。DTC仅3例阳性，肿瘤细胞较少，难以研究肿瘤细胞与骨微环境中细胞之间的相互作用。骨转移瘤标本中肿瘤细胞与骨微环境中细胞之间的相互作用研究是必要的

项目成果

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

• DOI: 10.1093/annonc/mdr435
• 发表时间: 2012-05-01
• 期刊: ANNALS OF ONCOLOGY
• 影响因子: 50.5
• 作者: Saad, F.;Brown, J. E.;Dansey, R.
• 通讯作者: Dansey, R.

Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis

• DOI: 10.1007/s10585-011-9379-7
• 发表时间: 2011-04-01
• 期刊: CLINICAL & EXPERIMENTAL METASTASIS
• 影响因子: 4
• 作者: Yuasa, Takeshi;Urakami, Shinji;Fukui, Iwao
• 通讯作者: Fukui, Iwao

Complete resection after imatinib treatment of a gastrointestinal stromal tumor of the ileum with peritoneal metastases: Report of a case

• DOI: 10.1007/s00595-008-4037-7
• 发表时间: 2010-03-01
• 期刊: SURGERY TODAY
• 影响因子: 2.5
• 作者: Akiyoshi, Takashi;Oya, Masatoshi;Muto, Tetsuichiro
• 通讯作者: Muto, Tetsuichiro

Safety, Efficacy and Pharmacokinetics of Neratinib (HKI-272) in Japanese Patients with Advanced Solid Tumors: A Phase 1 Dose-escalation Study

• DOI: 10.1093/jjco/hys012
• 发表时间: 2012-04-01
• 期刊: JAPANESE JOURNAL OF CLINICAL ONCOLOGY
• 影响因子: 2.4
• 作者: Ito, Yoshinori;Suenaga, Mitsukuni;Boku, Narikazu
• 通讯作者: Boku, Narikazu

原発不明がん適切な診断・治療のポイント

原发灶不明的癌症正确诊断和治疗的要点

• 发表时间: 2012
• 作者: 向井博文編、高橋俊二;他
• 通讯作者: 他